Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest $(EOI)$ from AstraZeneca plc, indicating their intent to join the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.